statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

89bio, Inc. (NASDAQ:ETNB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Two...

89bio, Inc. (NASDAQ:ETNB) Receives $28.83 Consensus Target Price from Analysts

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the Company or 89bio ) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization...

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

89bio, Inc. (NASDAQ:ETNB - Get Free Report)'s share price fell 6.8% during mid-day trading on Monday . The stock traded as low as $10.78 and last traded at $10.85. 182,176 shares traded hands during...

89bio (NASDAQ:ETNB)  Shares Down 6.8%

This price move could indicate a change in the trend, and may be a sell signal for investors...

89bio (ETNB, $10.71) price exceeded its 50-day Moving Average on April 01, 2024

Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on March 27. Thomas Smith has given hi...

Buy Rating Affirmed for 89bio's Pegozafermin: A Promising NASH Treatment with Strong Regulatory Endorsements

89bio (NASDAQ:ETNB  Get Free Report)s stock had its buy rating reissued by stock analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They...

HC Wainwright Reiterates "Buy" Rating for 89bio (NASDAQ:ETNB)

PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and...

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

This indicator may be signaling that ETNB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

89bio (ETNB, $11.34) entered Downtrend as Momentum indicator drops below 0 level on Mar 20, 2024

This indicator may be signaling ETNB's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

89bio (ETNB, $11.92) entered Uptrend as Momentum indicator ascends above 0 level on Mar 19, 2024

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Volume	76,469.00
52-Wk High	$22.93
52-Wk Low	$6.58

ETNB 89bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals